Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.


CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.277
Source Normalized Impact per Paper (SNIP) 2018: 0.446

Online
ISSN
2363-8915
See all formats and pricing
More options …
Volume 32, Issue 3

Issues

Need for pharmacogenetic studies on the prevalence of MTHFR mutations in Puerto Ricans and Hispanics

Raúl H. Morales-Borges
  • Corresponding author
  • President and Principal Investigator, Integrative Optimal Health of Puerto Rico, New Alliance Integrative Research, 29 Washington St. Suite # 107, San Juan, 00907-1509, Puerto Rico, Phone: (787) 722-0412, Fax: (787) 723-0554, E-mail:
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-09-01 | DOI: https://doi.org/10.1515/dmpt-2017-0010

Abstract

Methylenetetrahydrofolate reductase (MTHFR) mutations have been linked to many diseases. Evidence has been provided to prove that we need to perform pharmacogenetic studies regarding the prevalence of MTHFR mutations and diseases, risks, and the impact on folate requirement in general, but little has been published about Puerto Ricans. A multi center cross-sectional retrospective review study or a prospective pharmacogenetic study of valid genotypes and phenotypes of MTHFR mutations within the different populations of Puerto Ricans and Hispanics are recommended, because differences within them and within the general population are expected.

Keywords: Hispanics; MTHFR; mutation; pharmacogenetics; Puerto Ricans

References

  • 1.

    Stanley J, Garet E. Methylenetetrahydrofolate reductase deficiencies. https://www.douadweb.depauw.edu/$1-cfornari/dishen/webpage/index.htm. Accessed in December 2016.

  • 2.

    Marini NJ, Gin J, Ziegle J, Keho KH, Ginzinger D, Gilbert DA, et al. The prevalence of folate-remedial MTHFR enzyme variants in humans. Proc Natl Acad Sci USA 2008;105:8055–60.CrossrefGoogle Scholar

  • 3.

    Ayala-Rivera MA, Renta J, Garcia I, Garcia L, de La Vega A, Santiago-Borrero PJ, et al. Prevalence of common mutations of the MTHFR gene in a Puerto Rican population. Genet Med 1999;1:72 (abstract 112).CrossrefGoogle Scholar

  • 4.

    McAdrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylenetetrahydrofolate reductasa in African Americans. Thromb Res 1996;83:195–8.CrossrefGoogle Scholar

  • 5.

    Jiménez-Ramírez FJ, Castro LM, Ortiz C, Concepción J, Renta JY, Morales-Borges RH, et al. Role of treatment-modifying MTHFR 677C>T and 1298A>C polymorphisms in metformin-treated type-2 diabetes mellitus Puerto Rican patients with peripheral neuropathy: a pilot pharmacogenetic study. Drug Metab Pers Ther 2017;32:23–32.Google Scholar

  • 6.

    Morales-Borges RH. Prevalence of MTHFR C677T and A1298C mutations and thrombophilia in Puerto Rico. J Blood Disorders Transf 2014;5:213.Google Scholar

  • 7.

    Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, García R, Hernández G, et al. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther 2015;30: 239–49.PubMedGoogle Scholar

  • 8.

    Balley LB, Gregory JF. Polymorphism of methynenetetrahydrofolate reductasa and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999;129:919–22.Google Scholar

  • 9.

    Jarjour RA, Ammar S, Majdalawi R. Frequency of three prothrombotic polymorphisms among Syrian population: factor V G1691A, prothrombin G20210 and methylenetetrahydrofolate reductasa C677T. Ann Hum Biol 2015;10:1–4.Google Scholar

  • 10.

    Wang X, Fu J, Li O, Zeng D. Geographical and ethnic distributions of the MTHFR C677T, A1298C and MTRR A66G gene polymorphisms in Chinese populations: a meta-analysis. PLoS One 2016;11:e0152414.CrossrefWeb of SciencePubMedGoogle Scholar

  • 11.

    Jacques PF, Bostom AG, William RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.CrossrefPubMedGoogle Scholar

  • 12.

    Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM, et al. Common mutation in methylenetetrahydrofolate reductase. Circulation 1996;94:3074–8.CrossrefPubMedGoogle Scholar

  • 13.

    Perez AB, D’Almeida V, Vergani N, de Oliveira AC, de Lima FT, Brunoni D. Methylenetetrahydrofolate reductase (MTHFR): incidence of mutations C677T and A1298C in Brazilian population and its correlation with plasma homocysteine levels in spina bifida. Am J Med Genet A 2003;119A:20–5.PubMedCrossrefGoogle Scholar

  • 14.

    Varga EA, Sturm AC, Misita CP, Moll S. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation 2005;111:e289–93.PubMedCrossrefGoogle Scholar

  • 15.

    The National Alliance for Thrombosis and Thrombophilia website. Retrieved December 2016, at http://www.nattinfo.org.

  • 16.

    Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med 2013;15:153–6.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 17.

    Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet 2015;58:1–10.CrossrefWeb of SciencePubMedGoogle Scholar

About the article

Corresponding author: Raúl H. Morales-Borges, MD, President and Principal Investigator, Integrative Optimal Health of Puerto Rico, New Alliance Integrative Research, 29 Washington St. Suite # 107, San Juan, 00907-1509, Puerto Rico, Phone: (787) 722-0412, Fax: (787) 723-0554


Received: 2017-03-12

Accepted: 2017-08-03

Published Online: 2017-09-01

Published in Print: 2017-09-26


Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Drug Metabolism and Personalized Therapy, Volume 32, Issue 3, Pages 169–171, ISSN (Online) 2363-8915, ISSN (Print) 2363-8907, DOI: https://doi.org/10.1515/dmpt-2017-0010.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Briseida E. Feliciano-Astacio, Katrina Celis, Jairo Ramos, Farid Rajabli, Larry Deon Adams, Alejandra Rodriguez, Vanessa Rodriguez, Parker L. Bussies, Carolina Sierra, Patricia Manrique, Pedro R. Mena, Antonella Grana, Michael Prough, Kara L. Hamilton-Nelson, Nereida Feliciano, Angel Chinea, Heriberto Acosta, Jacob L. McCauley, Jeffery M. Vance, Gary W. Beecham, Margaret A. Pericak-Vance, and Michael L. Cuccaro
Frontiers in Genetics, 2019, Volume 10

Comments (0)

Please log in or register to comment.
Log in